Teduglutide
Also referenced as: Gattex
A GLP-2 analogue used in short bowel syndrome with dependence on parenteral support.
- Evidence grade
- AStrong Clinical Evidence
Strong Clinical Evidence
- Regulatory status
- FDA Approved for Specific Indication
Gattex is FDA-approved for parenteral-support-dependent short bowel syndrome in adults and children aged 1 year and older.
- Human data
- Yes
Registered clinical trials exist
- Last reviewed
- October 27, 2026
Overview
A GLP-2 analogue used in short bowel syndrome with dependence on parenteral support.
Gattex is FDA-approved for parenteral-support-dependent short bowel syndrome in adults and children aged 1 year and older.
Benefits apply to short bowel syndrome, not ordinary digestive discomfort, gut optimization or weight-loss goals.
Why It's Being Studied
- Short bowel syndrome
- Intestinal absorption
- Parenteral-support reduction
Mechanism of Action
GLP-2 receptor signalling enhances intestinal absorptive capacity rather than acting as a GLP-1 appetite suppressant.
GLP-2 receptor signalling enhances intestinal absorptive capacity rather than acting as a GLP-1 appetite suppressant. Benefits apply to short bowel syndrome, not ordinary digestive discomfort, gut optimization or weight-loss goals.
From molecular target to clinical evidence
Tap each stage to see what happens.
Background: Clinical Peptide Medicines
Clinical peptide medicines include endocrine treatments, antimicrobial drugs, receptor blockers and targeted diagnostic or cancer agents. They do not share one mechanism or one set of indications.
An approval belongs to a specific medicine and indication. A diagnostic tracer, an antibiotic and a hormone are not interchangeable wellness products; read each profile's own mechanism and prescribing source.
Research Areas & Routes Studied
- Short bowel syndrome
- Intestinal absorption
- Parenteral-support reduction
- Subcutaneous approved medicine
Evidence Summary
Randomized studies demonstrate reduced parenteral-support requirements, with some participants achieving independence.
Higher tiers carry more weight. Filled tiers have evidence for Teduglutide; tap to read it.
- Randomized studies demonstrate reduced parenteral-support requirements, with some participants achieving independence.
1 cited sources.
- Prescribing label1
Human clinical evidence
- Randomized studies demonstrate reduced parenteral-support requirements, with some participants achieving independence.
Reported Adverse Events in Research
- Intestinal growth can accelerate neoplastic processes; polyps, obstruction, biliary or pancreatic disease and fluid overload require surveillance.
Limitations of Current Evidence
- Benefits apply to short bowel syndrome, not ordinary digestive discomfort, gut optimization or weight-loss goals.
- Findings apply to the product, route and population studied; they do not establish benefits or safety for unrelated wellness uses or research-vial products.
How to Read This Research
- Is this a single molecule or a family of medicines?
- Is the use diagnostic, therapeutic or investigational?
- Does the quoted outcome match the exact product, formulation and population?
- Use the compound-specific mechanism above; this diagram describes drug development, not a shared biological pathway.
- Historical approval, present availability and off-label use are distinct questions.
- For radiopharmaceuticals and hospital medicines, specialist handling is part of the treatment context.
- Indication
- The condition and population for which a medicine is approved.
- Antagonist
- A compound that blocks activity at a receptor.
- Radiopharmaceutical
- A medicine containing a radioactive isotope for imaging or treatment.
Compare With Other Compounds
| Teduglutide | Trofinetide | |
|---|---|---|
| Evidence grade | A — Strong Clinical Evidence | B — Moderate Human Evidence |
| Regulatory status | FDA Approved for Specific Indication | FDA Approved for Specific Indication |
| Human data | Yes | Yes |
| Clinical trials | Registered trials exist | Registered trials exist |
| Research routes | Subcutaneous approved medicine | Oral approved medicine |
| Cited sources | 1 | 2 |
Frequently Asked Questions
Research References
- Prescribing label
Teduglutide — prescribing label